Medina Spirit cleared for Preakness after passing drug tests

Kentucky Derby winner Medina Spirit tested positive for the steroid betamethasone in post-Derby testing.

SHARE Medina Spirit cleared for Preakness after passing drug tests
Kentucky Derby winner and Preakness entrant Medina Spirit passed all drug tests and will be allowed to run in the second jewel of the Triple Crown.

Kentucky Derby winner and Preakness entrant Medina Spirit passed all drug tests and will be allowed to run in the second jewel of the Triple Crown.

Julio Cortez/AP

BALTIMORE — Medina Spirit has passed three rounds of prerace drug testing and been cleared to run in the Preakness on Saturday.

Maryland racing officials said Friday tests on the Kentucky Derby winner and fellow Bob Baffert-trained Concert Tour came back with nothing that would cause them to be scratched from the second leg of the Triple Crown. Baffert’s camp agreed to rigorous testing and monitoring of his horses as a condition of entry to the Preakness.

Medina Spirit tested positive for the steroid betamethasone in post-Derby testing. If a second round of testing there comes back positive, Medina Spirit will be disqualified and Mandaloun named winner of the Derby.

Medina Spirit was set as the 9-5 morning line favorite for the Preakness and Concert Tour the 5-2 second choice in the field of 10.

The Latest
Girls says the man is angry that she stood up for her mom in a disagreement about the couple’s sex and drinking habits.
Parent company Global Tetrahedron has big plans to diversify the satire news website’s revenue streams and bring back a print edition
Trout Unlimited’s Trout In The Classroom teaches young students about fish and the aquatic environment, capped by a day trip to get all wet.
Businesses and neighborhood associations in River North and nearby want the city to end the dining program because of traffic congestion, delays to first responders and other headaches caused by closing off a major street artery, a local restaurant executive writes.
High doses become routine patient care even when they make patients so ill that they skip doses or stop taking the drugs. “There’s a gap in FDA’s authority that results in patients getting excess doses of a drug at excess costs,” says Dr. Mark Ratain, a University of Chicago oncologist.